Physician profile
Robby Ayoub
NPI 1396958237
$15,887.03
in general payments reported to CMS, 2019-2025
59 companies · $3,981 in 2025
The $3,981 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,690 · 2020: $1,114 · 2021: $1,053 · 2022: $2,319 · 2023: $2,990 · 2024: $2,740 · 2025: $3,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,459 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,458.58 |
| Education | $252.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,201.61 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $1,950.04 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,594.64 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $1,075.26 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $879.10 | 2021-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $796.34 | 2019-2025 | Winrevair, Zerbaxa, Recarbrio |
| Grifols USA, LLC | $748.53 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $616.75 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $598.05 | 2019-2025 | |
| Harmony Biosciences LLC | $565.21 | 2021-2025 | Wakix |
| Verona Pharma, INC. | $508.08 | 2025 | Ohtuvayre |
| Philips North America LLC | $495.10 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Avadel Cns Pharmaceuticals, LLC | $235.94 | 2024-2025 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $187.70 | 2021-2024 | Glassia, Takhzyro |
| Electromed, INC. | $166.94 | 2019-2025 | Smartvest |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $163.01 | 2025 | Yupelri |
| Vanda Pharmaceuticals INC. | $144.18 | 2020-2023 | Hetlioz |
| Sunovion Pharmaceuticals INC. | $130.65 | 2019-2020 | |
| Baxter Healthcare | $118.96 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Volara System, Hillrom - Vest System Model 105 Home Care |
| Lilly USA, LLC | $114.91 | 2025 | Mounjaro, Zepbound |
| Ani Pharmaceuticals, INC. | $112.54 | 2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $94.68 | 2024-2025 | Zemaira |
| United Therapeutics Corporation | $92.99 | 2024-2025 | Tyvaso, Tyvaso |
| Insmed, INC. | $89.82 | 2022-2025 | Arikayce |
| Merz North America, INC. | $87.69 | 2020-2023 | Xeomin |
| Revance Therapeutics, INC. | $87.12 | 2024 | Daxxify |
| Genentech USA, INC. | $84.65 | 2019-2023 | Xolair |
| Amgen INC. | $82.75 | 2022-2024 | Tezspire |
| Pfizer INC. | $75.02 | 2023-2024 | |
| Cook Medical LLC | $60.51 | 2022 | |
| Axsome Therapeutics, INC. | $59.69 | 2023-2024 | Sunosi |
| Advanced Respiratory, INC | $58.62 | 2019-2020 | |
| Optinose US, INC. | $58.29 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $52.80 | 2023-2024 | |
| Exact Sciences Corporation | $52.38 | 2024 | Cologuard Collection Kit |
| Fisher & Paykel Healthcare INC | $50.64 | 2023 | Fisher & Paykel Healthcare |
| Phadia US INC. | $38.22 | 2019-2022 | |
| Abbvie INC. | $35.95 | 2022-2023 | Botox |
| Allergan, INC. | $35.92 | 2019 | |
| Novo Nordisk INC | $31.11 | 2025 | Wegovy |
| Urovant Sciences INC | $23.13 | 2022 | |
| Gilead Sciences, INC. | $23.06 | 2019 | |
| La Jolla Pharmaceutical Company | $22.86 | 2019 | |
| Paratek Pharmaceuticals, INC. | $22.08 | 2023 | Nuzyra |
| Pulmonx Corporation | $21.54 | 2020 | |
| Sanofi-Aventis U.S. LLC | $20.50 | 2020 | |
| Janssen Pharmaceuticals, INC | $19.26 | 2021 | |
| Sumitomo Pharma America, INC. | $18.63 | 2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $18.49 | 2023 | Quviviq |
| Nabriva Therapeutics, Plc | $16.87 | 2022 | |
| Circassia INC. | $15.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.70 | 2021 | |
| Cycle Pharmaceuticals INC | $11.36 | 2024 | Ormalvi |
| 3b Medical, INC. | $8.27 | 2025 | Luna |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robby Ayoub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.